Compare VLYPO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
| Metric | VLYPO | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 320.1M |
| IPO Year | 1994 | 2021 |
| Metric | VLYPO | LYEL |
|---|---|---|
| Price | $24.85 | $9.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.88 |
| AVG Volume (30 Days) | 3.8K | ★ 105.0K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.38 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.10 | $9.45 |
| 52 Week High | $25.64 | $45.00 |
| Indicator | VLYPO | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 27.89 |
| Support Level | $24.74 | N/A |
| Resistance Level | $25.03 | $15.38 |
| Average True Range (ATR) | 0.13 | 0.52 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 35.49 | 12.67 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.